Gestational diabetes is a type of diabetes that occurs during a woman's pregnancy, increasing the mother's risk of giving birth to a large baby for gestational age, with the result of premature births, fetal injuries, perinatal mortality and childbirth due toCaesarean section.
Gestational diabetes is also a risk factor for preeclampsia and gestational hypertension.Since the treatment of gestational diabetes can reduce the risk of adverse pregnancy results, practice guides recommend reviewing all non -diabetic pregnant women for the disease.
Scientists at the Brigham and Women's hospital (Boston, Ma, USA), carried out a case study and controls of 1,000 pregnant women who received standard prenatal care in the hospital.The study of five hundred women who had presented a normal glucose challenge test (controls) and five hundred women who showed abnormal results in this test were included within and required an oral tolerance test to the posterior glucose (patients).
The main objective of the equipment was to evaluate the accuracy of the diabetes biomarker, the plasma glycosylated CD59 (PGCD59), in the prediction of the results of the glucose challenge test, standard of attention, used to detect gestational diabetes.They evaluated if PGCD59 could predict the following: the results of the glucose challenge test (GCT) for the screening of gestational diabetes mellitus (GDM) (primary analysis);and the diagnosis of the GDM and the prevalence of large newborns for gestational age (LGA) (secondary analysis).
Scientists discovered that, compared to control individuals, the medium plasma value of GCD59 was 8.5 times higher in patients who had not exceeded the stimulation test with glucose and 10 times higher in the subgroup of these patients who metThe diagnostic criteria of gestational diabetes in the oral tolerance test after glucose.They also found that the highest levels of GCD59 plasma in gestation week 24-28 were associated with a higher prevalence of large newborns for gestational age, the higher the level, the higher the risk (4% higherfor patients in the lowest quartile of the plasma levels of GCD59, and 14% in the highest quartile).
Of the 58 large babies for the gestational age born of mothers who failed in the glucose challenge test, in this study, 80% were born of mothers who did not comply with the criteria of oral tolerance to gestational diabetes, but they hadMedium plasma levels of GCD59, seven times higher than women control with a normal glucose challenge test.These findings are consistent with other studies that show that women who fail in the glucose challenge test, but do not meet the criteria for gestational diabetes, are still at a higher risk of abnormal pregnancy results, including childbirthLarge babies for gestational age.
The team concluded that, since non -enzymatic glycation inactivated the CD59 complement inhibitor forming CD59 glycosylated (GCD59), they could use a specific immunoabsorbent trial (Elisa) for GCD59 in blood and showed that the plasma levels of GCD59 are significantly higher inWomen with type 2 diabetes and independently predict the response to the oral glucose tolerance test.
Dr. Jose A. Halperin, a hematologist and main author of the study said: “This is the first study that shows that a single measurement of GCD59 in plasma can be used as a simplified method to identify women who are at risk of failingIn the challenge test ofglucose and are at greater risk of developing gestational diabetes.These results suggest that a single measurement of GCD59 plasma, during weeks 24-28 can also help stratify the risk of giving birth larger babies among women with gestational glucose intolerance. ”The study was published in the April 2017 edition of the Diabetes Care magazine.
